000			nab a22 7a 4500
999			_c15890 _d15890
003			PC15890
005			20200818100735.0
008			200417b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9882 _aCastellano, Daniel _eOncología Médica
245	0	0	_aAbiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. _h[artículo]
260			_bThe Lancet. Oncology, _c2014
300			_a15(11):1263-8.
500			_aFormato Vancouver: Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN et al. Abiraterone Global EAP Investigators. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol. 2014 Oct;15(11):1263-8.
501			_aPMID: 25242048
504			_aContiene 13 referencias
505			_aErratum in: Lancet Oncol. 2014 Nov;15(12):e528.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc15890.pdf _ySolicitar documento
942			_2ddc _cART _n0